AVEO Stock Flies 40% on Impressive Tivozanib Data

AVEO stock

AVEO stock is gaining momentum this morning after AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) reported results from the second prespecified analysis of overall survival in the TIVO-3 trial.

Boost for Investors

Over the course of the past few months, there has been a lot of anticipation with regards to the second prespecified analysis trial of Aveo Oncology and its medicine TIVO-3. Today, the company released the data, and the results proved to be highly encouraging for the company.

The tests in question were performed on as many as 350 patients suffering from highly refractory metastatic renal ...

Read The Full Article On MicroSmallCap.com

Get early insight on hidden secret gems on MicroSmallCap. Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here.

All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.